Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/ computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

Authors

  • Bobby Shayegan
  • Katherine Zukotynski
  • François Bénard
  • Cynthia Ménard
  • Joda Kuk
  • Golmehr Sistani
  • Glenn Bauman
  • Patrick Veit-Haibach
  • Ur Metser

DOI:

https://doi.org/10.5489/cuaj.7268

Keywords:

PSMA PET/CT, prostate cancer, imaging

Abstract

Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) is increasingly being used worldwide as part of the clinical workup for men with prostate cancer. With high overall accuracy for the detection of prostate cancer, PSMA-targeted PET has an increasingly established role in the setting of biochemical failure after primary therapy and an evolving role in the setting of initial disease staging; its utility for guiding management in the setting of metastatic disease is less clear. Although the specificity is high, familiarization with potential pitfalls in the interpretation of PSMA-targeted PET, including knowledge of the causes for false-positive and negative examinations is critical. The aim of this best practice report is to provide an illustrative discussion of the current and evolving clinical indications for PSMA-targeted PET, as well as a review of physiological radiopharmaceutical biodistribution and potential imaging pitfalls.

Downloads

Download data is not yet available.

Downloads

Published

2021-03-01

How to Cite

Shayegan, B. ., Zukotynski, K. ., Bénard, F. ., Ménard, C. ., Kuk, J. ., Sistani, G. ., Bauman, G. ., Veit-Haibach, P. ., & Metser, U. . (2021). Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/ computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 15(6), 162–72. https://doi.org/10.5489/cuaj.7268

Issue

Vol. 15 No. 6 (2021): CUAJ June

Section

CUA Guideline

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.